Physician profile
Sameer Ansar
NPI 1942485735
$721.36
in general payments reported to CMS, 2019-2025
12 companies · $22.69 in 2025
The $22.69 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.72 · 2020: $194 · 2021: $142 · 2022: $143 · 2023: $79.14 · 2024: $95.11 · 2025: $22.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $196.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $241.01 | 2021-2023 | |
| Amgen INC. | $194.41 | 2020 | |
| Novo Nordisk INC | $94.75 | 2019-2024 | |
| Abbott Laboratories | $61.03 | 2022-2025 | Freestyle Libre 3 |
| Insulet Corporation | $50.73 | 2023 | Omnipod |
| Nevro Corp. | $19.22 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.45 | 2019 | |
| Lilly USA, LLC | $11.71 | 2022 | |
| Cequr Corporation | $11.65 | 2023 | Cequr Simplicity |
| Dexcom, INC. | $11.38 | 2021 | |
| Beta Bionics, INC. | $7.27 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Clarus Therapeutics INC. | $5.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Ansar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.